文献速递乳腺癌放疗

乳腺癌术后放疗区域与生物学亚型对局部区域复发分布的影响

Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-06-15

瑞典西南部2004-2008年923例乳腺癌术后局部区域放疗患者中,10年累积局部区域复发率为7.1%(95%CI 5.5-9.1)。56%的复发出现在照射野内,26%部分在野内;ER阴性(HR 4.6,P<.001)和HER2阳性(HR 2.4,P=.007)患者复发风险更高。ER-/HER2+肿瘤更多在野内复发(68%),提示复发分布与生物学亚型相关。

要点

  • 乳腺癌术后放疗后10年累积局部区域复发率为7.1%(95%CI 5.5-9.1)。
  • 56%的局部区域复发出现在照射野内,26%部分在野内。
  • ER阴性和HER2阳性患者局部区域复发风险显著高于ER阳性患者。

核心结论

  • 局部区域复发的发生率和位置似乎与原发性乳腺癌的生物学亚型相关,根据肿瘤生物学进行个体化局部区域放疗可能改善结局。

研究设计与样本

  • 回顾性队列研究,纳入瑞典西南部2004至2008年接受术后局部区域放疗的原发性乳腺癌患者923例,远处失败和死亡视为竞争风险。

主要发现

  • 10年累积局部区域复发率为7.1%(95%CI 5.5-9.1),923例中57例以局部区域复发为首发事件(30例局部复发、30例区域复发,其中3例同时局部和区域复发)。
  • 大多数局部区域复发病例完全(56%)或部分(26%)位于术后照射区域内,野外的区域复发最常见于锁骨上窝照射野头侧。
  • ER阴性患者较ER阳性患者局部区域复发风险更高(HR 4.6;P<.001;95%CI 2.5-8.4),HER2阳性患者同样更高(HR 2.4;P=.007;95%CI 1.3-4.7)。
  • ER阴性/HER2阳性肿瘤更多在野内复发(68%)而非边缘或野外(32%);野内复发中75%来自ER阴性或HER2阳性肿瘤,而边缘或野外复发中该比例为45%。
  • 新辅助治疗后腋窝达到完全病理缓解与较低的局部区域复发风险相关(P=.022)。

关键数值与推荐

  • 10年累积局部区域复发率为7.1%(95%CI 5.5-9.1)。
  • ER阴性患者局部区域复发HR为4.6(P<.001;95%CI 2.5-8.4),HER2阳性患者HR为2.4(P=.007;95%CI 1.3-4.7),均以ER阳性为参照。
  • ER阴性/HER2阳性肿瘤野内复发比例为68%,边缘或野外为32%。
  • 野内复发中ER阴性或HER2阳性肿瘤占75%,边缘或野外复发中占45%。
  • 腋窝新辅助治疗后完全病理缓解与局部区域复发风险降低相关(P=.022)。

临床怎么用

  • 对于ER阴性或HER2阳性乳腺癌患者,术后局部区域放疗靶区制定时需考虑其更高的局部区域复发风险及野内复发倾向。
  • 锁骨上窝照射野头侧是野外区域复发的常见部位,靶区勾画时需关注该区域覆盖。
  • 新辅助治疗后腋窝完全病理缓解可提示较低的局部区域复发风险,或可用于个体化放疗决策参考。

局限性

  • 本研究为回顾性病历复习,样本来自瑞典西南部单区域,结果外推需谨慎。
  • 局部区域复发事件数较少(57例),亚组分析统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate incidence and location of locoregional recurrence (LRR) in patients who have received postoperative locoregional radiation therapy (LRRT) for primary breast cancer. LRR-position in relation to applied radiotherapy and the primary tumor biological subtype were analyzed with the aim of evaluating current target guidelines and radiation therapy techniques in relation to tumor biology. METHODS AND MATERIALS: Medical records were reviewed for all patients who received postoperative LRRT for primary breast cancer in southwestern Sweden from 2004 to 2008 (N = 923). Patients with LRR as a first event were identified (n = 57; distant failure and death were considered competing risks). Computed tomographic images identifying LRR were used to compare LRR locations with postoperative LRRT fields. LRR risk and distribution were then related to the primary breast cancer biologic subtype and to current target guidelines. RESULTS: Cumulative LRR incidence after 10 years was 7.1% (95% confidence interval [CI], 5.5-9.1). Fifty-seven of the 923 patients in the cohort developed LRR (30 local recurrences and 30 regional recurrences, of which 3 cases were simultaneous local and regional recurrence). Most cases of LRR developed fully (56%) or partially (26%) within postoperatively irradiated areas. The most common location for out-of-field regional recurrence was cranial to radiation therapy fields in the supraclavicular fossa. Patients with an estrogen receptor negative (ER-) (hazard ratio [HR], 4.6; P < .001; 95% CI, 2.5-8.4) or HER2+ (HR, 2.4; P = .007; 95% CI, 1.3-4.7) primary breast cancer presented higher risks of LRR compared with those with ER+ tumors. ER-/HER2+ tumors more frequently recurred in-field (68%) rather than marginally or out-of-field (32%). In addition, 75% of in-field recurrences derived from an ER- or HER+ tumor, compared with 45% of marginal or out-of-field recurrences. A complete pathologic response in the axilla after neoadjuvant treatment was associated with a lower degree of LRR risk (P = .022). CONCLUSIONS: Incidence and location of LRR seem to be related to the primary breast cancer biologic subtype. Individualized LRRT according to tumor biology may be applied to improve outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Adra J, Lundstedt D, Killander F, et al. Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. Int J Radiat Oncol Biol Phys. 2019. PMID: 31212042. doi:10.1016/j.ijrobp.2019.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。